Back

Genetic Architecture and Myocardial Fibrotic Remodeling in Mitral Valve Prolapse

Small, A. M.; Yu, M.; Berrandou, T. E.; Georges, A.; Huff, M.; Morningstar, J. E.; Rand, S. A.; Koyama, S.; Lee, J.; Vy, H. M.; Farber-Eger, E.; Jin, S.; Dieterlen, M.-T.; Kontorovich, A. R.; Yang, T.-Y.; Do, R.; Dressen, M.; Krane, M.; Feirer, N.; Doppler, S. A.; Schunkert, H.; Trenkwalder, T.; Wells, Q. S.; Berger, K.; Ostrowski, S. R.; Sorensen, E.; Pedersen, O. B.; Bundgaard, J. S.; Ghouse, J.; Bundgaard, H.; Ganna, A.; Erikstrup, C.; Mikkelsen, C.; Bruun, M. T.; Aagaard, B.; Ullum, H.; Abner, E.; Slaugenhaupt, S. A.; Nadauld, L.; Knowlton, K.; Helgadottir, A.; Sveinbjornsson, G.; Gudbjart

2026-04-13 cardiovascular medicine
10.64898/2026.04.09.26350328 medRxiv
Show abstract

Mitral valve prolapse (MVP) is the most common cause of primary mitral regurgitation and is associated with the development of malignant arrhythmias, often in the context of myocardial fibrosis. The genetic architecture of MVP, and whether there are genetic factors explaining why only some individuals with MVP have adverse outcomes, remains poorly understood. We performed a meta-analysis of genome-wide association studies (GWAS) for MVP encompassing 21,517 cases among a total sample size of over 2.2 million individuals. We discovered 89 genomic risk loci for MVP, of which 72 were novel findings. Prioritization of causal genes and pathways using epigenetic and transcriptomic data from mitral valve and extra-valvular tissues replicated known gene associations to MVP including those involved in TGF-{beta} signaling and extracellular matrix biology, but additionally emphasized a role in MVP for biological pathways relevant to cardiomyocyte biology. Accordingly, we identified several MVP risk loci with pleiotropy to cardiomyopathies, especially hypertrophic cardiomyopathy, and demonstrated a significant genetic correlation between MVP and hypertrophic cardiomyopathy. Finally, we interrogated snRNA-seq data in human papillary muscle tissue from two individuals with severe MVP, characterizing genes associated with both risk of papillary muscle fibrosis and MVP.

Matching journals

The top 4 journals account for 50% of the predicted probability mass.

1
Circulation
66 papers in training set
Top 0.1%
21.5%
2
Nature Genetics
240 papers in training set
Top 0.3%
17.7%
3
Circulation: Genomic and Precision Medicine
42 papers in training set
Top 0.2%
8.7%
4
Nature Cardiovascular Research
28 papers in training set
Top 0.1%
8.0%
50% of probability mass above
5
Nature Communications
4913 papers in training set
Top 24%
8.0%
6
Journal of the American College of Cardiology
12 papers in training set
Top 0.1%
4.1%
7
eLife
5422 papers in training set
Top 21%
4.1%
8
Nature
575 papers in training set
Top 7%
3.4%
9
Science Translational Medicine
111 papers in training set
Top 2%
1.7%
10
European Heart Journal
16 papers in training set
Top 0.5%
1.6%
11
Journal of Clinical Investigation
164 papers in training set
Top 3%
1.6%
12
Cell Reports
1338 papers in training set
Top 26%
1.4%
13
JCI Insight
241 papers in training set
Top 4%
1.4%
14
Science
429 papers in training set
Top 16%
1.3%
15
Arteriosclerosis, Thrombosis, and Vascular Biology
65 papers in training set
Top 1%
1.2%
16
Cell Genomics
162 papers in training set
Top 5%
1.1%
17
European Heart Journal - Digital Health
15 papers in training set
Top 0.6%
0.8%
18
Science Advances
1098 papers in training set
Top 31%
0.7%
19
Cell
370 papers in training set
Top 18%
0.7%
20
Developmental Cell
168 papers in training set
Top 12%
0.7%
21
Cardiovascular Research
33 papers in training set
Top 1%
0.7%
22
Circulation Research
39 papers in training set
Top 1%
0.6%
23
PLOS Genetics
756 papers in training set
Top 18%
0.6%
24
Cell Reports Medicine
140 papers in training set
Top 10%
0.6%